studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), durvalumab plus tremelimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsMYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11] MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18] 0.92[0.79; 1.07]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,069moderatenot evaluable progression or deaths (PFS)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53] 1.05[0.72; 1.53]MYSTIC (DT ; PDL1>25%), 202010%325NAnot evaluable objective responses (ORR)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37] 0.87[0.55; 1.37]MYSTIC (DT ; PDL1>25%), 202010%325NAnot evaluable AE (any grade)detailed resultsMYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96] MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24] 0.48[0.28; 0.84]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37] MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35] 0.97[0.76; 1.24]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable AE leading to death (grade 5)detailed resultsMYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11] MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59] 2.48[1.45; 4.24]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsMYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10] MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93] 1.49[1.08; 2.05]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47] 2.14[1.32; 3.47]MYSTIC (DT ; all population), 202010%723NAnot evaluable SAE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04] 1.93[1.22; 3.04]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable STRAE (any grade)detailed resultsMYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24] MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87] 1.35[0.96; 1.89]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202027%1,039moderatenot evaluable STRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21] 1.43[0.92; 2.21]MYSTIC (DT ; all population), 202010%723NAnot evaluable TRAE (any grade)detailed resultsMYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44] MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30] 0.24[0.13; 0.43]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020268%1,039moderatenot evaluable TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77] MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60] 0.47[0.31; 0.70]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020246%1,039moderatenot evaluable TRAE leading to death (grade 5)detailed resultsMYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71] MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13] 1.66[0.48; 5.76]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsMYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35] MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03] 1.31[0.90; 1.92]MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 202020%1,039moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78] 2.95[1.51; 5.78]MYSTIC (DT ; all population), 202010%723NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82] 5.73[0.29; 114.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19] 0.01[0.00; 0.19]MYSTIC (DT ; all population), 202010%723NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01] 0.06[0.00; 1.01]MYSTIC (DT ; all population), 202010%723NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13] 13.52[0.76; 239.13]MYSTIC (DT ; all population), 202010%723NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16] 0.47[0.02; 14.16]MYSTIC (DT ; all population), 202010%723NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82] 0.95[0.24; 3.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82] 1.90[0.06; 56.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28] 4.35[0.93; 20.28]MYSTIC (DT ; all population), 202010%723NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03] 1.09[0.39; 3.03]MYSTIC (DT ; all population), 202010%723NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13] 13.52[0.76; 239.13]MYSTIC (DT ; all population), 202010%723NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82] 1.90[0.06; 56.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82] 1.90[0.06; 56.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82] 5.73[0.29; 114.82]MYSTIC (DT ; all population), 202010%723NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30] 0.16[0.02; 1.30]MYSTIC (DT ; all population), 202010%723NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20] 0.01[0.00; 0.20]MYSTIC (DT ; all population), 202010%723NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17] 7.74[0.96; 62.17]MYSTIC (DT ; all population), 202010%723NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Rash TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23] 0.95[0.06; 15.23]MYSTIC (DT ; all population), 202010%723NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42] 0.03[0.00; 0.42]MYSTIC (DT ; all population), 202010%723NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18] 0.07[0.00; 1.18]MYSTIC (DT ; all population), 202010%723NAnot evaluable Alopecia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Anaemia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28] 0.12[0.05; 0.28]MYSTIC (DT ; all population), 202010%723NAnot evaluable Asthenia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05] 0.86[0.36; 2.05]MYSTIC (DT ; all population), 202010%723NAnot evaluable Back pain AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80] 0.63[0.10; 3.80]MYSTIC (DT ; all population), 202010%723NAnot evaluable Constipation AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07] 1.90[0.17; 21.07]MYSTIC (DT ; all population), 202010%723NAnot evaluable Cough AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11] 1.43[0.40; 5.11]MYSTIC (DT ; all population), 202010%723NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17] 2.12[0.73; 6.17]MYSTIC (DT ; all population), 202010%723NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33] 1.11[0.37; 3.33]MYSTIC (DT ; all population), 202010%723NAnot evaluable Fatigue AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31] 1.31[0.52; 3.31]MYSTIC (DT ; all population), 202010%723NAnot evaluable Nausea AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25] 0.63[0.18; 2.25]MYSTIC (DT ; all population), 202010%723NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19] 0.01[0.00; 0.19]MYSTIC (DT ; all population), 202010%723NAnot evaluable Pruritus AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95] 0.95[0.02; 47.95]MYSTIC (DT ; all population), 202010%723NAnot evaluable Rash AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23] 0.95[0.06; 15.23]MYSTIC (DT ; all population), 202010%723NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42] 0.03[0.00; 0.42]MYSTIC (DT ; all population), 202010%723NAnot evaluable Vomiting AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09] 0.13[0.02; 1.09]MYSTIC (DT ; all population), 202010%723NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsMYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64] 2.86[0.30; 27.64]MYSTIC (DT ; all population), 202010%723NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:20 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 634,861